Ipratropium bromide 0.06% (42mcg/spray); aqueous soln. Ipratropium bromide, an anticholinergic (parasympatholytic) agent, has antisecretory properties which inhibit secretions from the serous and ...

Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 | Active ...

Objectives: To compare the efficacy and tolerability of formoterol (12 or 24µg twice daily) alone with combined ipratropium bromide and fenoterol in the treatment of chronic obstructive pulmonary ...

Global pharma major Lupin Limited (Lupin) announced the launch of ipratropium bromide nasal solution (nasal spray), 0.03% and 0.06%, in the United States. Ipratropium bromide nasal solution (nasal ...

Ipratropium bromide 20mcg, albuterol 100mcg (equivalent to 120mcg albuterol sulfate); per actuation; inhalation spray; CFC-free. Based on studies, ipratropium bromide appears to inhibit vagally ...

Short-acting Anticholinergic Drugs in Asthma Ipratropium bromide was introduced into the management of obstructive airway diseases in the mid-1970s.

Ipratropium bromide also may cause urinary retention. COMBIVENT should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder-neck obstruction.

Lupin launches Ipratropium Bromide nasal spray in US, bioequivalent to Atrovent. The product addresses rhinitis and targets a $63 million market opportunity.

About Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol COMBIVENT Inhalation Aerosol is indicated for use in patients with chronic obstructive pulmonary disease (COPD) on ...

Ipratropium bromide, a component of COMBIVENT Inhalation Aerosol and COMBIVENT RESPIMAT, is an anticholinergic and may cause urinary retention.